Pharma and Biotech


FTSE 100

  • Change Today:
  • 52 Week High: 2,263.00
  • 52 Week Low: 1,400.00
  • Currency: UK Pounds
  • Shares Issued: 4,067.35m
  • Volume: 8,805,624
  • Market Cap: £57,960m
  • RiskGrade: 129

GSK says respiratory vaccine shows 'significant' efficacy in trial

By Frank Prenesti

Date: Friday 10 Jun 2022

LONDON (ShareCast) - (Sharecast News) - GlaxoSmithKline said its vaccine for respiratory virus had shown "statistically significant" and clinically meaningful efficacy in adults aged 60 years and above in a phase 3 trial.
The company said the primary endpoint of the trial was "exceeded with no unexpected safety concerns observed" and would now start talks with regulators to start immediately with anticipated regulatory submissions in the second half of the year.

Respiratory syncytial virus is contagious and affects the lungs and breathing passages. It is one of the major remaining infectious diseases for which there is currently no vaccine or specific treatment, GSK said on Friday.

"These data suggest our RSV vaccine candidate offers exceptional protection for older adults from the serious consequences of RSV infection," said Dr Hal Barron, GSK's Chief Scientific Officer.

"RSV remains one of the few major infectious diseases without a vaccine, and these data have the potential to meaningfully impact the treatment of RSV and may reduce the 360,000 hospitalisations and more than 24,000 deaths worldwide each year."

Email this article to a friend

or share it with one of these popular networks:

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.


GSK Market Data

Currency UK Pounds
Share Price 1,425.00p
Change Today 19.00p
% Change 1.35 %
52 Week High 2,263.00
52 Week Low 1,400.00
Volume 8,805,624
Shares Issued 4,067.35m
Market Cap £57,960m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
60.44% below the market average60.44% below the market average60.44% below the market average60.44% below the market average60.44% below the market average
1.59% below the sector average1.59% below the sector average1.59% below the sector average1.59% below the sector average1.59% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 7
Buy 1
Neutral 13
Sell 0
Strong Sell 1
Total 22
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q2 Q1
Ex-Div 18-Aug-22 19-May-22
Paid 06-Oct-22 01-Jul-22
Amount 16.25p 14.00p

Trades for 16-Aug-2022

Time Volume / Share Price
17:11 7,366 @ 1,425.76p
17:11 35,232 @ 1,428.07p
17:11 29,594 @ 1,424.99p
17:11 37,725 @ 1,429.68p
17:11 19,687 @ 1,435.27p

GSK Key Personnel

CEO Emma Walmsley
CFO Iain Mackay

Top of Page